Latest filing published 13 Jul 2026 for Esperion Therapeutics, Inc..
Across 1 buy signal with a settled T+90 return. Return basis: close on the day after publication.
Benjamin Halladay discloses dealings in Esperion Therapeutics, Inc. to SEC (Form 4). We count 17 filings; the first trade dates from 9 December 2022 and the latest from 13 July 2026.
Every open-market trade on record is a sale: 11 sales worth €104k. Outside the open market, there are 5 share grants. So far in 2026, the count stands at no purchases and 2 sales.
Most recently, on 13 July 2026, the filings show a transaction in Esperion Therapeutics, Inc. Between a trade and the moment it shows up on SEC (Form 4), the median delay is 1 day. The legal deadline for a Form 4 is two business days after the transaction. A sale on its own says little: insiders also sell to pay tax, fund a purchase or diversify. Source: insider filings from SEC (Form 4). Past trades are no guide to future returns.
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
17 of 17 declarations